INC Research Holdings Inc (NASDAQ:INCR) fell 5.7% on Thursday . The company traded as low as $40.50 and last traded at $41.30. 1,958,274 shares were traded during mid-day trading, an increase of 61% from the average session volume of 1,219,125 shares. The stock had previously closed at $43.80.

A number of brokerages have recently weighed in on INCR. TheStreet upgraded shares of INC Research from a “c” rating to a “b-” rating in a report on Monday, November 6th. Credit Suisse Group began coverage on shares of INC Research in a report on Wednesday, October 11th. They issued an “outperform” rating and a $68.00 price objective for the company. Jefferies Group upgraded shares of INC Research from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $62.50 to $69.00 in a report on Monday, October 9th. Robert W. Baird reaffirmed a “buy” rating and issued a $67.00 target price on shares of INC Research in a research note on Monday, October 9th. Finally, Zacks Investment Research downgraded shares of INC Research from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. INC Research currently has a consensus rating of “Buy” and an average price target of $50.78.

The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27. The company has a market cap of $4,309.45, a P/E ratio of 18.94, a P/E/G ratio of 1.27 and a beta of 1.09.

INC Research (NASDAQ:INCR) last issued its earnings results on Thursday, November 9th. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.63 by ($0.09). INC Research had a positive return on equity of 14.42% and a negative net margin of 4.29%. The firm had revenue of $592.21 million during the quarter, compared to analysts’ expectations of $604.95 million. During the same period in the previous year, the firm earned $0.64 earnings per share. The firm’s quarterly revenue was up 128.2% compared to the same quarter last year. equities research analysts expect that INC Research Holdings Inc will post 2.15 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of INCR. Lee Thomas H Partners LP purchased a new position in INC Research during the 3rd quarter valued at $1,316,644,000. BlackRock Inc. increased its position in INC Research by 82.3% during the 2nd quarter. BlackRock Inc. now owns 6,461,899 shares of the company’s stock valued at $378,020,000 after purchasing an additional 2,917,605 shares during the period. Janus Henderson Group PLC purchased a new position in INC Research during the 2nd quarter valued at $99,424,000. State Street Corp increased its position in INC Research by 112.8% during the 2nd quarter. State Street Corp now owns 1,769,353 shares of the company’s stock valued at $103,508,000 after purchasing an additional 937,864 shares during the period. Finally, Point72 Asset Management L.P. increased its position in INC Research by 1,337.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 598,039 shares of the company’s stock valued at $31,277,000 after purchasing an additional 556,439 shares during the period. 99.50% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “INC Research (INCR) Trading Down 5.7%” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/inc-research-incr-trading-down-5-7/1797186.html.

About INC Research

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Receive News & Ratings for INC Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research and related companies with Analyst Ratings Network's FREE daily email newsletter.